Trade Mark Journal No.2025/045 7 November 2025
UK00004281519 21 October 2025 (5,35,42,44)
- Class 5
- Pharmaceuticals; therapeutics; pharmaceuticals and therapeutics for the treatment of liver diseases, cirrhosis, hepatitis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), alcoholic liver diseases, liver fibrosis, primary biliary cholangitis, fibrotic diseases and metabolic diseases; pharmaceuticals and therapeutics for the treatment of obesity, sarcopenia, metabolic disorders and muscular disorders; pharmaceuticals and therapeutics for the treatment of conditions affecting the liver; pharmaceuticals and therapeutics for use in the field of metabolics; RNA medicines; RNA synthesis inhibitors; culture media for cultivating human cells and tissue; cells and tissue for medical or clinical use.
- Class 35
- Data entry, collection, compilation, analysis and management services; information, advisory and consultancy services relating to all the aforesaid services.
- Class 42
- Software as a Service (SaaS); Software as a Service (SaaS) for use in relation to pharmaceuticals, DNA analysis, genomic phenotyping, pharmaceutical research and drug discovery; application service provider featuring software for use in the visualisation of data; database design; technical data analysis; technical data analysis services in relation to pharmaceuticals, DNA analysis, genomic phenotyping, pharmaceutical research and drug discovery; drug screening for scientific research purposes; scientific and technical modelling services for use in relation to the research, design and development of pharmaceuticals, drugs and medicines; research and development of siRNA and mRNA drugs; pharmaceutical product evaluation; testing of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid services.
- Class 44
- Medical services in relation to cirrhosis, hepatitis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), alcoholic liver diseases, liver fibrosis, primary biliary cholangitis, fibrotic diseases, metabolic diseases, the treatment of obesity, sarcopenia, metabolic disorders, muscular disorders and the treatment of conditions affecting the liver; provision of medical information about genomic phenotyping and the treatment of conditions affecting the liver; provision of medical information and data for use in relation to the research, design and development of pharmaceuticals, drugs and medicines; information, advisory and consultancy services relating to all the aforesaid services.
Ochre Bio Ltd
Representative: Kilburn & Strode LLP